• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

So Much for a Red Wave, Crypto Rescue, Weighing Obesity Drugs, US-Taiwan Talk

Plus, the Treasury yield spread moved in the wrong direction Tuesday, signaling possible economic hardship ahead.
By STEPHEN GUILFOYLE
Nov 09, 2022 | 07:27 AM EST
Stocks quotes in this article: DIS, TSM, AMGN, NVO, LLY, DHI, RBLX, U, WYNN

Curveball

Zero dark-thirty. Now, that was a long night.

It started off with The Walt Disney Company (DIS) . Disney kicked off the evening when it reported a truly awful quarter in terms of corporate execution shortly after the closing bell. Markets for the most part had performed well on Tuesday, as they had on Monday and the Friday before that. Why wouldn't they? Everyone knows that a gridlocked government is good for equities, the president's party always does poorly in midterm elections, and that this president bears very low approval ratings two years into his first term.

Perhaps we should have considered the fact that this president's predecessor, a lightning rod for inspiring both his loyalists as well as his opponents, was still out there... endorsing candidates and more than hinting at his own political return. For there would be no red wave on Tuesday night.

There are enough seats that remain uncalled in both the Senate and the House for the GOP to potentially take control of both legislative chambers. However, that possibility is looking more and more remote as right now, the only seat in the Senate that flipped turned blue, and the House will be far closer than had been projected.

True, even with a small majority in the House, there would be a gridlocked government, but there can be no denial that whatever you think of President Joe Biden -- and do not accuse me of being political, for I truly try to keep my opinions to myself -- Biden has easily outperformed almost all recent to semi-recent presidents in his first midterm election. Perhaps this owes more to his predecessor's involvement than his own performance. Regardless of cause or reason, what reads on the scoreboard at the end of the game is what matters, and the scoreboard tells a tale of GOP disappointment.

Potential Market Impact

If one believes that the equity rally of the past few days was simply traders (and algorithms) front-running an expected red wave in anticipation of increased GOP influence in Washington , then one must also believe that this recent strength will quickly dissipate. On that point, US equity index futures are trading lower very early on Wednesday morning. If one believes that this recent equity market strength was simply reliant upon any gridlock at all -- the reason being that GOP control of even just the House by a slim margin would be enough to thwart the Biden agenda and still slow inflation through arrested fiscal largess and an inability to bring forth new regulation -- then that game is still afoot, and could be for a little while.

Marketplace

While by most measures US equities put a third day of gains to the tape on Tuesday, trading volume remained below recent norms for a second straight day. This rally very likely has much to do with a US dollar that decreased in valuation versus a basket of its reserve currency peers for a third day and Treasury yields that decreased for the session.

Investors bought most of the Treasury curve ahead of election night and ahead of this afternoon's coming auction of $35 billion in US 10-Year paper. However, the yield spread between that 10-Year Note and the US Three-Month T-Bill that had been improving and moving toward un-inverting moved in the wrong direction on Tuesday, signaling probable economic hardship in our future.

There was perhaps a hint of what was to come in Tuesday's equity market performance. Winners beat losers by a rough 3 to 2 at the New York Stock Exchange and by the slimmest of margins at the Nasdaq Market Site as advancing volume took moderate shares of 62.7% and 54.5% respectively, of composite trade for names listed at those exchanges. I have already mentioned the less-than-convincing aggregate trading volume.

On the bright side...

... The S&P 500 found support at its 50-day simple moving average (SMA) on Tuesday. We may learn early just how much stickiness this level has. It has not had all that much of an ability to hold on recent moves above that line.

On the not-so-bright side...

... The Nasdaq Composite was quite rudely rejected on Tuesday at its 21-day exponential moving average (EMA). Recent history suggests that if the Nasdaq Composite can take this line, that it can be held for more than a week at a minimum.

Bitcoin

What happened was that FTX was hit with about $6 billion in withdrawals over the three days going into Tuesday morning as Sol, which is/was the native token of the Solana blockchain that is/had been used by both FTX and Alameda Research, dropped dramatically. This forced Sam Bankman-Fried to reach out to billionaire and sometime antagonist CZ Zhao of Binance for a rescue. Binance has agreed to acquire FTX, but not FTX (US), which is a separate exchange in a "non-binding" deal. This implies that the agreement could still fall though.

I see Bitcoin trading below $17,500 a piece this morning, down almost 7% after bottoming at $17,172 on Tuesday, which was down 17% for the day at the time. Nearly every other digital token or coin was down significantly as well. Can cryptocurrencies, as an asset class, stabilize here at these levels? Anything is possible. I have long felt that this asset class was grossly overvalued and I still do.

That said, front-month gold futures gained nearly $100 per ounce from last Thursday's low to Tuesday's high. I saw a last sale for gold this morning at roughly $1,707.

Under the Radar...

Outside of Beijing, that is. A US delegation led by assistant US trade representative Terry McCartin met with Taiwanese counterparts in New York City on Tuesday in meetings meant to improve economic ties and trade relations between the two nations. The meetings covered agriculture and digital technology specifically as Taiwan, thanks to Taiwan Semiconductor (TSM) , is the world's leading foundry and a dominant player in the advanced semiconductor manufacturing space. Taiwan is also a key client-state for US defense and aerospace firms and a strategic geo-political partner as that island nation is not viewed as sovereign by the mainland Chinese government.

A follow-up meeting is planned later this month as US trade representative Katherine Tai plans to travel to Asia for the Nov. 13-17 ministers' meeting of the Asia-Pacific Economic Cooperation (APEC) organization. Taiwan is a member and Tai's Taiwanese counterpart, John Deng, is expected to attend. Simultaneously, the US and Chinese governments are believed to be trying to arrange a side meeting between Presidents Joe Biden and Xi Jinping at the G-20 summit in Bali on Nov. 15 and 16. Wonder how that's going to go...

Obesity

I am sure that most readers noticed Amgen's (AMGN) Olpasiran did well in Phase 2 clinical trials and will now move on to Phase 3 testing. Being tested for obesity, patients in the "low dose" group lost an average of 7.2% of their body weight over 85 days. Patients in the "high-dose" group lost an average of 14.5% of their body weight. This will put Amgen in direct competition with Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Mounjaro, which is already approved for the treatment of diabetes but is in clinical testing as a treatment of obesity as well. AMGN ran 5.55% to $292.39 on Tuesday.

In Phase 3 testing, patients receiving Wegovy for 68 weeks (not days) lost close to 17% of their body weight. Wegovy, however, remains in short supply. Mounjaro, when tested at the highest dosage for 72 weeks, showed an average loss of 22.5% of one's body weight. At the 12-week mark (84 days), making the test comparable to the one done by Amgen, Mounjaro produced an average weight loss of 8% of body weight.

I am long LLY largely for this reason and am expecting the approval process to potentially go smoothly for Mounjaro as the drug is already approved and in use for a completely different indication.

Mr. Toad's Wild Ride

Given the time of day and space already taken up in this column, I am going to have to come back with a piece on Disney's awful quarterly earnings. I have received multiple requests overnight to cover this name this morning for Real Money and Real Money Pro. I will not leave you in a lurch. After all, I am long a small to midsize position myself. My analysis will be available to you shortly.

Economics (All Times Eastern)

06:00 - MBA 30 Year Mortgage Rate (Weekly): Last 7.06%.

06:00 - MBA Mortgage Applications (Weekly): Last -0.5%.

10:00 - Wholesale Inventories (Sep-rev): Flashed 0.8% m/m.

10:30 - Oil Inventories (Weekly): Last -3.115M.

10:30 - Gasoline Stocks (Weekly): Last -1.257M.

13:00 - Ten Year Note Auction: $35B.

The Fed (All Times Eastern)

11:00 - Speaker: Richmond Fed Pres. Tom Barkin.

Today's Earnings Highlights (Consensus EPS Expectations)

Before the Open: (DHI) (5.15), (RBLX) (-.36)

After the Close: (U) (-.15), (WYNN) (-1.01)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Guilfoyle was long DIS and LLY equity.

TAGS: Drug Approvals | Earnings | Economy | Interest Rates | Investing | Politics | Stocks | Treasury Bonds | Pharmaceuticals | Real Money | Cryptocurrency

More from Stocks

Market Surprises With Rally Before Fed Day

James "Rev Shark" DePorre
Jan 31, 2023 4:38 PM EST

The bears are absolutely convinced that this market move is unjustified -- but what we're seeing has very little to do with fundamentals or the economy.

Why Is Today the Big Day? Dividends

Jim Collins
Jan 31, 2023 3:20 PM EST

The Fed has once again unwittingly unleashed the power of compounding.

Doug Kass: Believe Half of What You See and None of What You Hear

Doug Kass
Jan 31, 2023 2:15 PM EST

Ignore the growing and 'made-up' market narratives promulgated daily.

Shark School of Trading: Anatomy of a Breakout

James "Rev Shark" DePorre
Jan 31, 2023 12:00 PM EST

I'm looking for a move that would constitute a new closing high.

Honeywell Is Showing Chart Weakness Ahead of Earnings

Bruce Kamich
Jan 31, 2023 11:30 AM EST

Let's look over the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:27 PM EST REAL MONEY

    LIVE EVENT: Chris Versace and "Sarge" Guilfoyle Share Their Stock Market Insights

    This Monday, Jan. 30, at 12 p.m., our very own exp...
  • 11:48 AM EST REAL MONEY

    Watch Doug Kass on the Daily Rundown!

    In today's Action Alerts PLUS Daily Rundown, Doug ...
  • 11:03 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend On Real Money

    It's time to start using this power to build great...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login